Acamprosate in the treatment of alcohol dependence: clinical and economic considerations

References

• Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol. Ther.111(3), 855–876 (2006).
   PubMed Web of Science ®Google Scholar
• Fuller RK, Branchey L, Brightwell DR et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA256(11), 1449–1455 (1986).
   PubMed Web of Science ®Google Scholar
• Mark TL, Kranzler HR, Poole VH et al. Barriers to the use of medications to treat alcoholism. Am. J. Addict.12(4), 281–294 (2003).
   PubMed Web of Science ®Google Scholar
• Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction99(7), 811–828 (2004).
   PubMed Web of Science ®Google Scholar
• Mann K, Kiefer F. Acamprosate in the treatment of alcoholism: mechanisms and perspectives. Future Neurol.1(3), 277–284 (2006).
   Google Scholar
• Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res. World22(1), 13–24 (1998).
   PubMed Web of Science ®Google Scholar
• De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs19(6), 517–537 (2005).
   PubMed Web of Science ®Google Scholar
• Kranzler H. Medications to treat heavy drinking: are we there yet? Addiction101(2), 153–154 (2006).
   PubMedGoogle Scholar
• Findings of three online surveys, conducted among 1000 members of the general public (aged 20+), 300 general practitioners and internists (aged 25+), and 503 people in recovery (aged 25–50), Peter D. Hart Research Associates 10–26 August (2005).
   Google Scholar
• Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am. J. Addict.12(Suppl. 1), S3–S11 (2003).
   PubMed Web of Science ®Google Scholar
• Campral®, package insert. Forest Pharmaceuticals Inc., Subsidiary of Forest Laboratories Inc., MO, USA (2004).
   Google Scholar
• Saivin S, Hulot T, Chabac S et al. Clinical pharmacokinetics of acamprosate. Clin. Pharmacokinet.35(5), 331–345 (1998).
   PubMed Web of Science ®Google Scholar
• Chabenat C, Chretien P, Daoust M et al. Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate. Methods Find. Exp. Clin. Pharmacol.10(5), 311–317 (1988).
   PubMed Web of Science ®Google Scholar
• Wilde MI, Wagstaff AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs53(6), 1038–1053 (1997).
   PubMed Web of Science ®Google Scholar
• Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Acamprosate in Relapse Prevention of Alcoholism. Proceedings of the 1st Campral Symposium. Soyka M (Ed.). Springer-Verlag, Stuttgart, Germany 47–64 (1995).
   Google Scholar
• Johnson BA, O’Malley SS, Ciraulo DA et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J. Clin. Psychopharmacol.23(3), 281–293 (2003).
   PubMed Web of Science ®Google Scholar
• Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk–benefits assessment. Eur. Neuropsychopharmacol.13(6), 469–475 (2003).
   PubMed Web of Science ®Google Scholar
• Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J. Stud. Alcohol15, 148–156 (2005).
   Google Scholar
• Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol. Clin. Exp. Res.28(1), 51–63 (2004).
   PubMed Web of Science ®Google Scholar
• De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict. Behav.29(7), 1325–1339 (2004).
   PubMed Web of Science ®Google Scholar
• Boismare F, Daoust M, Moore N et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol. Biochem. Behav.21(5), 787–789 (1984).
   PubMed Web of Science ®Google Scholar
• Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol4(2), 97–102 (1987).
   PubMed Web of Science ®Google Scholar
• Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol.26(2), 129–137 (1991).
   PubMed Web of Science ®Google Scholar
• Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology18(2), 125–133 (1998).
   PubMed Web of Science ®Google Scholar
• Spanagel R, Putzke J, Stefferl A, Schobitz B, Zieglgansberger W. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur. J. Pharmacol.305(1–3), 45–50 (1996).
   PubMed Web of Science ®Google Scholar
• Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur. J. Pharmacol.437(1–2), 55–61 (2002).
   PubMed Web of Science ®Google Scholar
• Cowen MS, Adams C, Kraehenbuehl T, Vengeliene V, Lawrence AJ. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addict. Biol.10(3), 233–242 (2005).
   PubMed Web of Science ®Google Scholar
• Madamba SG, Schweitzer P, Zieglgansberger W, Siggins GR. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol. Clin. Exp. Res.20(4), 651–658 (1996).
   PubMed Web of Science ®Google Scholar
• Dahchour A, De Witte P, Bolo N et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res.82(2), 107–114 (1998).
   PubMed Web of Science ®Google Scholar
• Berton F, Francesconi WG, Madamba SG, Zieglgansberger W, Siggins GR. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABAB receptors in nucleus accumbens neurons. Alcohol. Clin. Exp. Res.22(1), 183–191 (1998).
   PubMed Web of Science ®Google Scholar
• Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol. Clin. Exp. Res.22(4), 802–809 (1998).
   PubMed Web of Science ®Google Scholar
• al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol. Clin. Exp. Res.22(4), 810–814 (1998).
   PubMed Web of Science ®Google Scholar
• Popp RL, Lovinger DM. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur. J. Pharmacol.394(2–3), 221–231 (2000).
   PubMed Web of Science ®Google Scholar
• Mayer S, Harris B, Gibson DA et al. Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcohol. Clin. Exp. Res.26(5), 655–662 (2002).
   PubMed Web of Science ®Google Scholar
• Harris BR, Prendergast MA, Gibson DA et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol. Clin. Exp. Res.26(12), 1779–1793 (2002).
   PubMed Web of Science ®Google Scholar
• Harris BR, Gibson DA, Prendergast MA et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol. Clin. Exp. Res.27(11), 1724–1735 (2003).
   PubMed Web of Science ®Google Scholar
• Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu. Rev. Med.49, 173–184 (1998).
   PubMed Web of Science ®Google Scholar
• Nagy J, Muller F, Laszlo L. Cytotoxic effect of alcohol-withdrawal on primary cultures of cortical neurones. Drug Alcohol Depend.61(2), 155–162 (2001).
   PubMedGoogle Scholar
• Otsuki M, Davidson M, Goodenough S et al.In vivo pharmacological study of spermine-induced neurotoxicity. Neurosci. Lett.196(1–2), 81–84 (1995).
   PubMedGoogle Scholar
• Sparapani M, Dall’Olio R, Gandolfi O, Ciani E, Contestabile A. Neurotoxicity of polyamines and pharmacological neuroprotection in cultures of rat cerebellar granule cells. Exp. Neurol.148(1), 157–166 (1997).
   PubMedGoogle Scholar
• Gibson DA, Harris BR, Prendergast MA et al. Polyamines contribute to ethanol withdrawal-induced neurotoxicity in rat hippocampal slice cultures through interactions with the NMDA receptor. Alcohol. Clin. Exp. Res.27(7), 1099–1106 (2003).
   PubMedGoogle Scholar
• Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR. Potential neuroprotective effects of acamprosate. Alcohol. Clin. Exp. Res.26(4), 586–592 (2002).
   PubMed Web of Science ®Google Scholar
• Koob GF. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction101(Suppl. 1), 23–30 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry159(10), 1642–1652 (2002).
   PubMed Web of Science ®Google Scholar
• Bolo N, Nedelec JF, Muzet M et al. Central effects of acamprosate: part 2. Acamprosate modifies the brain in vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatry Res.82(2), 115–127 (1998).
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Schneider U, Haacker T et al. Acamprosate reduces motor cortex excitability determined by transcranial magnetic stimulation. Neuropsychobiology42(4), 183–186 (2000).
   PubMedGoogle Scholar
• Boeijinga P, Parot P, Danel T et al. Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment during alcohol abstinence. Neuropsychobiology50(1), 71–77 (2004).
   PubMedGoogle Scholar
• Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol.38(2), 135–141 (2003).
   PubMed Web of Science ®Google Scholar
• Lhuintre JP, Daoust M, Moore ND et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet1(8436), 1014–1016 (1985).
   PubMed Web of Science ®Google Scholar
• Lhuintre JP, Moore N, Tran G et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol.25(6), 613–622 (1990).
   PubMed Web of Science ®Google Scholar
• Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics? J. Pharm. Belg.51(2), 65–68 (1996).
   PubMedGoogle Scholar
• Pelc I, Verbanck P, Le Bon O et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br. J. Psychiatry171(1), 73–77 (1997).
   PubMed Web of Science ®Google Scholar
• Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J. Stud. Alcohol65(1), 136–139 (2004).
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry60(1), 92–99 (2003).
   PubMed Web of Science ®Google Scholar
• Morley KC, Teesson M, Reid SC et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction101(10), 1451–1462 (2006).
   PubMed Web of Science ®Google Scholar
• Pelc I, Le Bon O, Verbanck P, Lehert P, Opsomer L. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo controlled double-blind multi-centre study. In: Novel Pharmacological Interventions for Alcoholism. Naranjo CA, Sellers E (Eds). Springer-Verlag, NY, USA 348–352 (1992).
   Google Scholar
• Ladewig D, Knecht T, Leher P, Fendl A. Acamprosate – a stabilizing factor in long-term withdrawal of alcoholic patients. Ther. Umsch.50(3), 182–188 (1993).
   PubMedGoogle Scholar
• Geerlings PJ, Ansoms C, Van den Brink W. Acamprosate and prevention of relapse alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patients in the Netherlands, Belgium and Luxembourg. Eur. Addict. Res.3(3), 129–137 (1997).
   Web of Science ®Google Scholar
• Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction92(11), 1537–1546 (1997).
   PubMed Web of Science ®Google Scholar
• Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol.35(2), 176–187 (2000).
   PubMed Web of Science ®Google Scholar
• Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol.35(2), 202–209 (2000).
   PubMed Web of Science ®Google Scholar
• Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol.36(5), 413–418 (2001).
   PubMed Web of Science ®Google Scholar
• Paille FM, Guelfi JD, Perkins AC et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol.30(2), 239–247 (1995).
   PubMed Web of Science ®Google Scholar
• Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatry53(8), 673–680 (1996).
   PubMed Web of Science ®Google Scholar
• Whitworth AB, Fischer F, Lesch OM et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet347(9013), 1438–1442 (1996).
   PubMed Web of Science ®Google Scholar
• Barrias JA, Chabac S, Ferreira L. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatr. Clin.18(2), 149–160 (1997).
   Google Scholar
• Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol. Clin. Exp. Res.22(3), 573–579 (1998).
   PubMed Web of Science ®Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA295(17), 2003–2017 (2006).
   PubMed Web of Science ®Google Scholar
• Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J. Psychiatr. Res.40(5), 383–393 (2006).
   PubMed Web of Science ®Google Scholar
• Mason BJ, Lehert P. Women and alcoholism: a meta-analysis of outcome predictors based on 935 female patients in 16 acamprosate trials. Alcohol. Clin. Exp. Res.31(Suppl. 6), A58 (2007).
   Google Scholar
• Schneider E, Saikali K, Zhang D, Gage A. Acamprosate decreases the severity and duration of relapse and aids in post-relapse recovery of abstinence in alcohol-dependent patients. Presented at: The 158th Meeting of the American Psychiatric Association. Toronto, ON, Canada, 20–25 May 2006.
   Google Scholar
• Chick J, Lehert P, Landron F. Does acamprosate improve reduction of drinking as well as aiding abstinence? J. Psychopharmacol.17(4), 397–402 (2003).
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Jaffe AJ, Chang G et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry49(11), 881–887 (1992).
   PubMed Web of Science ®Google Scholar
• Heinala P, Alho H, Kiianmaa K et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol.21(3), 287–292 (2001).
   PubMed Web of Science ®Google Scholar
• Balldin J, Berglund M, Borg S et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol. Clin. Exp. Res.27(7), 1142–1149 (2003).
   PubMed Web of Science ®Google Scholar
• Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs21(3), 213–237 (2007).
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration, Office of Applied Statistics. Treatment Episode Data Set (TEDS). Highlights – 2004. National Admissions to Substance Abuse Treatment Services. DASIS Series: S-34, DHHS Publication No. (SMA) 06–4206, Rockville, MD, (2006).
   Google Scholar
• Staines GL, Magura S, Foote J, Deluca A, Kosanke N. Polysubstance use among alcoholics. J. Addict. Dis.20(4), 53–69 (2001).
   PubMed Web of Science ®Google Scholar
• O’Toole TP, Conde-Martel A, Gibbon JL et al. Substance-abusing urban homeless in the late 1990s: how do they differ from non-substance-abusing homeless persons? J. Urban. Health81(4), 606–617 (2004).
   PubMed Web of Science ®Google Scholar
• Gross MM, Goodenough DR, Hastey J, Lewis E. Experimental study of sleep in chronic alcoholics before, during, and after four days of heavy drinking with a nondrinking comparison. Ann. NY Acad. Sci.215, 254–265 (1973).
   PubMed Web of Science ®Google Scholar
• Gross MM, Hastey JM. Slow wave sleep and carry-over of functional tolerance and physical dependence in alcoholics. Adv. Exp. Med. Biol.59, 477–493 (1975).
   PubMedGoogle Scholar
• Williams HL, Rundell OH Jr. Altered sleep physiology in chronic alcoholics: reversal with abstinence. Alcohol Clin. Exp. Res.5(2), 318–325 (1981).
   PubMed Web of Science ®Google Scholar
• Adamson J, Burdick JA. Sleep of dry alcoholics. Arch. Gen. Psychiatry28(1), 146–149 (1973).
   PubMed Web of Science ®Google Scholar
• Brower KJ, Aldrich MS, Robinson EA, Zucker RA, Greden JF. Insomnia, self-medication, and relapse to alcoholism. Am. J. Psychiatry158(3), 399–404 (2001).
   PubMed Web of Science ®Google Scholar
• Landolt HP, Gillin JC. Sleep abnormalities during abstinence in alcohol-dependent patients. Aetiology and management. CNS Drugs15(5), 413–425 (2001).
   PubMed Web of Science ®Google Scholar
• Meyer RE. Prospects for a rational pharmacotherapy of alcoholism. J. Clin. Psychiatry50(11), 403–412 (1989).
   PubMed Web of Science ®Google Scholar
• Staner L, Boeijinga P, Danel T et al. Effects of acamprosate on sleep during alcohol withdrawal: a double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. Alcohol. Clin. Exp. Res.30(9), 1492–1499 (2006).
   PubMed Web of Science ®Google Scholar
• Kathmann N, Soyka M, Gallinat J, Hegerl U. Effects of acamprosate on verbal learning in healthy young subjects. In: Acamprosate in Relapse Prevention of Alcoholism. Soyka, M (Ed.). Springer-Verlag, NY, USA 105–110 (1996).
   Google Scholar
• Malenka RC. The role of postsynaptic calcium in the induction of long-term potentiation. Mol. Neurobiol.5(2–4), 289–295 (1991).
   PubMed Web of Science ®Google Scholar
• O’Mahony JF, Doherty B. Intellectual impairment among recently abstinent alcohol abusers. Br. J. Clin. Psychol.35(Pt 1), 77–83 (1996).
   PubMed Web of Science ®Google Scholar
• Schneider U, Wohlfarth K, Schulze-Bonhage A et al. Effects of acamprosate on memory in healthy young subjects. J. Stud. Alcohol60(2), 172–175 (1999).
   PubMed Web of Science ®Google Scholar
• Smith DE, McCrady BS. Cognitive impairment among alcoholics: impact on drink refusal skill acquisition and treatment outcome. Addict. Behav.16(5), 265–274 (1991).
   PubMed Web of Science ®Google Scholar
• McCrady BS, Smith DE. Implications of cognitive impairment for the treatment of alcoholism. Alcohol. Clin. Exp. Res.10(2), 145–149 (1986).
   PubMed Web of Science ®Google Scholar
• Mason BJ, Goodman AM, Dixon RM et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology27(4), 596–606 (2002).
   PubMed Web of Science ®Google Scholar
• Soyka M, Aichmuller C, Preuss U, Moller HJ. Effects of acamprosate on psychomotor performance and driving ability in abstinent alcoholics. Pharmacopsychiatry31(6), 232–235 (1998).
   PubMedGoogle Scholar
• Holder HD, Blose JO. The reduction of health care costs associated with alcoholism treatment: a 14-year longitudinal study. J. Stud. Alcohol53(4), 293–302 (1992).
   PubMed Web of Science ®Google Scholar
• Harwood HJ, Fountain D, Fountain G. Economic cost of alcohol and drug abuse in the United States, 1992: a report. Addiction94(5), 631–635 (1999).
   PubMed Web of Science ®Google Scholar
• Ray GT, Mertens JR, Weisner C. The excess medical cost and health problems of family members of persons diagnosed with alcohol or drug problems. Med. Care.45(2), 116–122 (2007).
   PubMed Web of Science ®Google Scholar
• Schadlich PK, Brecht JG. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study. Pharmacoeconomics13(6), 719–730 (1998).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Neeser K, Weiss C et al. The long-term cost–effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol.35(5), 478–492 (2000).
   PubMed Web of Science ®Google Scholar
• Portella E, Ridao M, Salvat M, Carrillo E. The health costs of alcoholism. Aten. Primaria22(5), 279–284 (1998).
   PubMedGoogle Scholar
• Annemans L, Vanoverbeke N, Tecco J, D’Hooghe D. Economic evaluation of Campral (acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. Eur. Addict. Res.6(2), 71–78 (2000).
   PubMed Web of Science ®Google Scholar
• Rychlik R, Siedentop H, Pfeil T, Daniel D. Cost–effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Eur. Addict. Res.9(2), 59–64 (2003).
   PubMed Web of Science ®Google Scholar
• Poldrugo F, Haeger DA, Comte S, Walburg J, Palmer AJ. A critical review of pharmacoeconomic studies of acamprosate. Alcohol Alcohol.40(5), 422–430 (2005).
   PubMedGoogle Scholar
• Weycker D, Oster G, Haim Erder M. Economic benefits of acamprosate therapy in alcohol-dependent patients: an update. Presented at: The 18th Annual Academy of Managed Care Pharmacy. Seattle, WA, USA, 5–8 April 2006.
   Google Scholar
• Littleton JM, De Witte P, Litten R et al. Challenges to medications development in treating alcohol dependence: an international perspective. Alcohol Alcohol.39(4), 271–275 (2004).
   PubMedGoogle Scholar
• Pelc I, Ansoms C, Lehert P et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol. Clin. Exp. Res.26(10), 1529–1538 (2002).
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration, Office of Applied Statistics. National Survey of Substance Abuse Treatment Services (N-SSATS): 2005. Data on Substance Abuse Treatment Facilities. DASIS Series: S-34, DHHS Publication No. (SMA) 06–4206, Rockville, MD (2006).
   Google Scholar